Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer

12 Nov 2015

Abstract excerpt

In metastatic colorectal cancer (CRC), actionable genetic lesions represent potential clinical opportunities. NTRK1, 2, and 3 gene rearrangements encode oncogenic fusions of the tropomyosin-receptor kinase (TRK) family of receptor tyrosine kinases in different tumor types. The TPM3-NTRK1 rearrangement is a recurring event in CRC that renders tumors sensitive to TRKA kinase inhibitors in preclinical models. We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colorectal Cancer Treatments and Studies
Share to Melanoma and MAPK Pathways
Share to PI3K/AKT/mTOR signaling in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26563355
DOI: 10.1093/jnci/djv306

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal CancerPMID 26563355Read ↗

Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer.Semantic proximity Read ↗

Tropomyosin Receptor Kinase Inhibitors for the Treatment of TRK Fusion CancerSemantic proximity Read ↗

TRK Inhibition: A New Tumor-Agnostic Treatment StrategySemantic proximity Read ↗

NTRK fusion positive colorectal cancer is a unique subset of CRC with high TMB and microsatellite instability.Semantic proximity Read ↗

Emerging Targeted Therapy for Tumors with NTRK Fusion Proteins.Semantic proximity Read ↗

China special issue on gastrointestinal tumors-NTRK fusion in a large real-world population and clinical utility of circulating tumor DNA genotyping to guide TRK inhibitor treatment.Semantic proximity Read ↗

TRKing down an old oncogene in a new era of targeted therapy.Semantic proximity Read ↗

NTRK Fusion in Non-Small Cell Lung Cancer: Diagnosis, Therapy, and TRK Inhibitor ResistanceSemantic proximity Read ↗

A review of NTRK fusions in cancerSemantic proximity Read ↗

Foretinib Overcomes Entrectinib Resistance Associated with the NTRK1 G667C Mutation in NTRK1 Fusion-Positive Tumor Cells in a Brain Metastasis Model.Semantic proximity Read ↗

Antitumor activity of larotrectinib in tumors harboring NTRK gene fusions: a short review on the current evidenceSemantic proximity Read ↗

Targeting TRK: A Fast Tracked Application of Precision Oncology and Future DirectionsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.